ArticleMolecular and cellular biochemistry2026
Combination of sitagliptin and mangiferin mitigates testicular damage induced by paclitaxel via mediating Sestrin2/Keap1/Nrf2 signaling pathway.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncofertility is an emergent discipline that combines many strategies to preserve fertility for cancer patients who are at risk of becoming infertile due to the gonadotoxicity of therapy. Although paclitaxel (PTX) is frequently used as an antineoplastic, testicular damage is regretfully linked to its use. Sitagliptin (SIT) and mangiferin (MAN) have promising antioxidant, anti-inflammatory, and anti-apoptotic actions. Thus, the goal of this study is to explore the ameliorative impact of SIT, MAN, and their combination on the PTX-provoked testicular toxicity model. Testicular toxicity is triggered by a single dose of PTX (8 mg/kg). Adult male albino rats were randomly classified into 5 equal groups: control, PTX, and PTX groups treated with SIT, MAN, or their combination for 14 days. The testes and epididymides were gathered for biochemical assessments and sperm analysis, respectively. Histopathological, ultrastructural, and immunohistochemical examinations of caspase-3, cleaved caspase-3, NLRP3, Nrf2, and Keap1 were investigated. Treated groups with SIT, MAN, or their combination significantly increased serum testosterone, testicular LDH-C content, sperm count, and motility compared to PTX group. Testicular catalase activity, Nrf2, and sestrin2 levels were significantly elevated compared to the PTX group. The treated groups counteracted the increase in serum ALP, ACP, LDH-C, testicular MDA, caspase-1, IL-1ꞵ, and IL-18 contents, NLRP3, Keap1, caspase-3, and cleaved caspase-3 expressions induced by PTX. Such therapeutic effects were more pronounced in combination than monotherapy. In conclusion, our study found that combining SIT and MAN had a remarkably beneficial impact on PTX-induced testicular toxicity by mediating the Sestrin2/Keap1/Nrf2 signaling pathway.
Indexed as
Identifiers
42384342What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.